BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly Stock Surges on Successful Weight-Loss Drug Trial
Eli Lilly Stock Surges on Successful Weight-Loss Drug Trial
21
1
BTCCSquare news:
Eli Lilly's stock soared nearly 6% on Tuesday, outpacing the S&P 500's modest 0.4% gain, following promising phase 3 trial results for its oral weight-loss drug orforglipron. The medication demonstrated significant efficacy, with participants losing an average of 10.5% of their body weight over 72 weeks, compared to 2.2% for the placebo group.
The drug also showed positive effects on blood sugar levels, positioning it as a potential blockbuster in the cardiometabolic health market. Eli Lilly now plans to expedite regulatory submissions to the FDA and other global agencies, aiming to address high patient demand for effective weight-loss treatments.
By:
